

Bronchiectasis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

<https://marketpublishers.com/r/BE7E345207F6EN.html>

Date: November 2025

Pages: 90

Price: US\$ 4,900.00 (Single User License)

ID: BE7E345207F6EN

Abstracts

Bronchiectasis is a chronic respiratory condition characterized by the abnormal and irreversible dilation of the bronchial tubes (airways) in the lungs. This widening of the airways leads to impaired mucus clearance, recurrent infections, and inflammation of the lungs. The condition can result in chronic cough, excessive mucus production, and frequent lung infections. Bronchiectasis may arise as a primary disease or be secondary to other conditions such as cystic fibrosis, chronic obstructive pulmonary disease (COPD), or immunodeficiency disorders. It can also result from recurrent respiratory infections, tuberculosis, or inhalation of foreign bodies.

The bronchiectasis market is driven by an increasing global prevalence of the condition, growing awareness, advancements in treatment modalities, and an aging population that is more susceptible to respiratory diseases. Chronic respiratory conditions like COPD, cystic fibrosis, and autoimmune disorders often lead to bronchiectasis, contributing to a growing patient base that requires effective treatments to manage symptoms and prevent disease progression. As the global population ages, the prevalence of bronchiectasis is rising. Moreover, the increasing recognition of bronchiectasis as a common cause of chronic respiratory symptoms is leading to higher diagnosis rates, fueling the demand for treatments that manage inflammation, infections, and mucus production. For instance, the increasing prevalence of COPD, a major risk factor for bronchiectasis, is driving the adoption of long-term inhaled therapies like tiotropium (Spiriva) and fluticasone to manage airflow obstruction and improve patient outcomes.

In addition, the treatment landscape for bronchiectasis has evolved significantly in recent years, shifting from symptomatic treatments to more targeted, disease-modifying

therapies. Macrolide antibiotics (e.g., azithromycin) are now routinely used to reduce exacerbations, prevent infections, and improve quality of life for patients.

Also, the development of biologics and immunomodulators represents the next frontier for treating bronchiectasis, especially in patients with autoimmune or inflammatory conditions. These therapies aim to target specific immune system pathways, reducing inflammation and preventing lung damage. There is growing interest in the role of biologics such as anti-TNF-alpha agents and interleukin inhibitors, which could significantly change the management of patients with chronic inflammation in bronchiectasis.

Despite the advances in treatment, challenges remain, such as high costs associated with biologic therapies and inhaled treatments, which can limit access, particularly in lower-income healthcare systems. Additionally, treatment adherence remains a significant issue, as bronchiectasis is a chronic condition requiring long-term management. Ensuring that patients stick to prescribed regimens, especially when involving complex inhalation therapies or daily antibiotics, remains a barrier to effective treatment.

The growing recognition of bronchiectasis as a distinct clinical condition is opening the door to more precision medicine approaches. This trend is driven by advancements in genetic profiling and biomarker discovery, which allow for targeted treatments tailored to specific patient profiles. Personalized therapies, particularly those aimed at cystic fibrosis-related bronchiectasis and autoimmune-driven bronchiectasis, are expected to gain traction in the market. Biologics and immunomodulators are among the most promising treatment options in personalized medicine, targeting specific pathways involved in airway inflammation and damage.

Contents

Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note

1. GLOBAL BRONCHIECTASIS MARKET: INDUSTRY OUTLOOK

1.1 Market Overview
1.2 Epidemiological Analysis of Bronchiectasis, By Region
1.3 Regulatory Landscape
1.4 Key Trends
1.5 Clinical Trial Analysis
1.6 Market Dynamics
 1.6.1 Impact Analysis
 1.6.2 Market Drivers
 1.6.3 Market Restraint
 1.6.4 Market Opportunities

2. GLOBAL BRONCHIECTASIS MARKET, BY REGION, \$MILLION, 2023-2035

2.1 North America
 2.1.1 Market Dynamics
 2.1.2 Market Sizing and Forecast
 2.1.2.1 North America Bronchiectasis Market, by Country
 2.1.2.1.1 U.S.
2.2 Europe
 2.2.1 Market Dynamics
 2.2.2 Market Sizing and Forecast
 2.2.2.1 Europe Bronchiectasis Market, by Country
 2.2.2.1.1 Germany
 2.2.2.1.2 U.K.
 2.2.2.1.3 France
 2.2.2.1.4 Italy
 2.2.2.1.5 Spain
2.3 Asia-Pacific

- 2.3.1 Market Dynamics
- 2.3.2 Market Sizing and Forecast
 - 2.3.2.1 Asia-Pacific Bronchiectasis Market, by Country
 - 2.3.2.1.1 Japan

3. GLOBAL BRONCHIECTASIS MARKET -COMPETITIVE LANDSCAPE AND COMPANY PROFILES

- 3.1 Key Strategies and Development, by Company
 - 3.1.1 Funding Activities
 - 3.1.2 Mergers and Acquisitions
 - 3.1.3 Regulatory Approvals
 - 3.1.4 Partnerships, Collaborations and Business Expansions
- 3.2 Company Profiles
 - 3.2.1 Insmmed Incorporated
 - 3.2.1.1 Overview
 - 3.2.1.2 Product Portfolio
 - 3.2.1.3 Target Customers
 - 3.2.1.4 Key Personnel
 - 3.2.1.5 Analyst View
 - 3.2.2 AstraZeneca
 - 3.2.2.1 Overview
 - 3.2.2.2 Product Portfolio
 - 3.2.2.3 Target Customers
 - 3.2.2.4 Key Personnel
 - 3.2.2.5 Analyst View
 - 3.2.3 ZAMBON COMPANY S.P.A.
 - 3.2.3.1 Overview
 - 3.2.3.2 Product Portfolio
 - 3.2.3.3 Target Customers
 - 3.2.3.4 Key Personnel
 - 3.2.3.5 Analyst View
 - 3.2.4 Chiesi Farmaceutici S.p.A
 - 3.2.4.1 Overview
 - 3.2.4.2 Product Portfolio
 - 3.2.4.3 Target Customers
 - 3.2.4.4 Key Personnel
 - 3.2.4.5 Analyst View
 - 3.2.5 Armata Pharmaceuticals

- 3.2.5.1 Overview
- 3.2.5.2 Product Portfolio
- 3.2.5.3 Target Customers
- 3.2.5.4 Key Personnel
- 3.2.5.5 Analyst View
- 3.2.6 Merck
 - 3.2.6.1 Overview
 - 3.2.6.2 Product Portfolio
 - 3.2.6.3 Target Customers
 - 3.2.6.4 Key Personnel
 - 3.2.6.5 Analyst View
- 3.2.7 Sanofi
 - 3.2.7.1 Overview
 - 3.2.7.2 Product Portfolio
 - 3.2.7.3 Target Customers
 - 3.2.7.4 Key Personnel
 - 3.2.7.5 Analyst View
- 3.2.8 Boehringer Ingelheim International GmbH
 - 3.2.8.1 Overview
 - 3.2.8.2 Product Portfolio
 - 3.2.8.3 Target Customers
 - 3.2.8.4 Key Personnel
 - 3.2.8.5 Analyst View
- 3.2.9 Others

4. RESEARCH METHODOLOGY

List Of Figures

LIST OF FIGURES

Figure: Bronchiectasis Market (by Scenario), \$Million, 2024, 2030, and 2035

Figure: Global Bronchiectasis Market, 2024 and 2035

Figure: Global Bronchiectasis Market Key Trends, Impact Analysis, 2023-2035

Figure: North America Bronchiectasis Market, \$Million, 2023-2035

Figure: Europe Bronchiectasis Market, \$Million, 2023-2035

Figure: Asia-Pacific Bronchiectasis Market, \$Million, 2023-2035

List Of Tables

LIST OF TABLES

Table: Market Snapshot

Table: Global Bronchiectasis Market Dynamics, Impact Analysis

Table: Global Bronchiectasis Market (by Region), \$Million, 2023-2035

I would like to order

Product name: Bronchiectasis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

Product link: <https://marketpublishers.com/r/BE7E345207F6EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BE7E345207F6EN.html>